Viracta Therapeutics reports Q3 EPS (33c), consensus (30c)

“During our recently held R&D Day, we provided multiple clinical and strategic updates, which further positioned Nana-val as a differentiated potential therapeutic option for patients with EBV-associated cancers,” said Mark Rothera, President and Chief Executive Officer of Viracta. “Preliminary results from the PTCL cohort of the NAVAL-1 trial demonstrated overall and complete response rates of 40%, which are consistent with results from our previous Phase 1b/2 study and exceeds the current standard of care for this patient population with high unmet medical need. We continue to believe that Nana-val is an ideal candidate for the accelerated approval pathway and we remain on track to complete enrollment of the Nana-val PTCL Stage 2 cohort and engage with FDA in 2024.”